GUJTHEM

Gujarat Themis Biosyn Share Price

 

 

Invest in Gujarat Themis Biosyn with 2.36X leverage

Invest with MTF

Performance

  • Low
  • ₹372
  • High
  • ₹382
  • 52 Week Low
  • ₹208
  • 52 Week High
  • ₹479
  • Open Price₹373
  • Previous Close₹377
  • Volume76,192

Investment Returns

  • Over 1 Month -15.6%
  • Over 3 Month -0.99%
  • Over 6 Month + 17.81%
  • Over 1 Year + 11.73%

Smart Investing Starts Here Start SIP with Gujarat Themis Biosyn for Steady Growth!

Invest Now

Gujarat Themis Biosyn Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 85.7
  • PEG Ratio
  • -10.3
  • Market Cap Cr
  • 4,141
  • P/B Ratio
  • Average True Range
  • 14.67
  • EPS
  • 4.43
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -9.2
  • RSI
  • 25.43
  • MFI
  • 19.98

Gujarat Themis Biosyn Financials

Gujarat Themis Biosyn Technicals

EMA & SMA

Current Price
₹380.00
+ 2.35 (0.62%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹410.97
  • 50 Day
  • ₹416.83
  • 100 Day
  • ₹400.44
  • 200 Day
  • ₹370.03

Resistance and Support

376.38 Pivot Speed
  • R3 389.67
  • R2 385.48
  • R1 380.57
  • S1 371.47
  • S2 367.28
  • S3 362.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Gujarat Themis Biosyn has an operating revenue of Rs. 155.48 Cr. on a trailing 12-month basis. An annual revenue de-growth of -12% needs improvement, Pre-tax margin of 43% is great, ROE of 19% is exceptional. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 41 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Gujarat Themis Biosyn Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-05-20 Audited Results & Final Dividend
2025-02-14 Quarterly Results
2024-10-25 Quarterly Results
Date Purpose Remarks
2025-09-05 FINAL Rs.0.67 per share(67%)Final Dividend
2024-02-22 INTERIM Rs.0.75 per share(75%)Interim Dividend
2022-12-02 INTERIM Rs.4.40 per share(88%)Interim Dividend
2021-11-25 INTERIM Rs.2.00 per share(40%)Interim Dividend
2021-11-25 SPECIAL Rs.5.00 per share(100%)Special Dividend
View Gujarat Themis Biosyn Dividend History Arrow
Date Purpose Remarks
2023-10-10 Split Rs.0.00 split from Rs. 5/- to Re. 1/-.
Date Purpose Remarks
2024-08-09 Bonus Re.0.00 issue in the ratio of 1:2 of Re. 1/-.

Gujarat Themis Biosyn F&O

Gujarat Themis Biosyn Shareholding Pattern

70.86%
1.16%
2.95%
0.01%
18.72%
6.3%

About Gujarat Themis Biosyn

  • NSE Symbol
  • GUJTHEM
  • BSE Symbol
  • 506879
  • Managing Director
  • Dr. Sachin D Patel
  • ISIN
  • INE942C01045

Similar Stocks to Gujarat Themis Biosyn

Gujarat Themis Biosyn FAQs

Gujarat Themis Biosyn share price is ₹380 As on 09 December, 2025 | 01:26

The Market Cap of Gujarat Themis Biosyn is ₹4140.7 Cr As on 09 December, 2025 | 01:26

The P/E ratio of Gujarat Themis Biosyn is 85.7 As on 09 December, 2025 | 01:26

The PB ratio of Gujarat Themis Biosyn is 18.5 As on 09 December, 2025 | 01:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23